Next, we evaluated the diagnostic performance of both plasma biomarkers for identifying amyloid PET positivity in cognitively unimpaired individuals, as well as identifying biological AD (amyloid PET and tau PET positivity) in cognitively impaired individuals evaluated by dementia specialists (Fig. 3A and B; Supplementary Table S3). This evidence concerns the gene MAPT and Alzheimer disease.